NIH Highlighted Topic: Breaking Barriers: Integrating Immunology and Neuroscience to Transform AD/ADRD Research and Bring a Better Understanding of the Aging Brain
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on integrating immunology, neuroscience, and aging research to transform understanding, prevention, diagnosis, and treatment of Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD). This highlighted topic supports multidisciplinary projects investigating how immune system dysfunction, neuroinflammation, infections, autoimmunity, environmental exposures, and aging-related immune changes contribute to neurodegeneration and cognitive decline.
NIH is particularly interested in projects that bridge traditionally separate disciplines — including immunology, neuroscience, infectious disease, computational biology, and environmental health — to uncover novel mechanisms underlying AD/ADRD pathogenesis. Companies developing neuroimmunology platforms, AI-enabled biomarker systems, precision diagnostics, computational modeling tools, organoid systems, immunotherapeutics, microbiome analytics platforms, or neurodegenerative disease monitoring technologies may be strong candidates for funding.
Areas of interest include neuroimmune crosstalk, innate and adaptive immune dysfunction, immunosenescence, neuroinflammation, infectious disease interactions, autoimmunity, microbiome effects, exposome-related neurotoxicity, environmental exposure modeling, biomarker discovery, risk stratification, and immunotherapeutic development. NIH is also encouraging projects leveraging organoids, microphysiological systems, human tissues, AI and machine learning, computational neuroscience, and translational model systems to improve understanding of aging brain biology and AD/ADRD progression.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by the National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), and National Institute of Environmental Health Sciences (NIEHS), all of which are seeking transformative innovations that improve neurodegenerative disease diagnostics, immune-based therapies, environmental health understanding, and precision approaches to Alzheimer’s disease and aging brain research.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of neuroimmunology technologies, biomarkers, computational systems, diagnostics, immunotherapies, and translational neuroscience platforms related to AD/ADRD and aging brain research.
Eligible activities may include:
AI and machine learning platforms for AD/ADRD biomarker discovery and risk prediction
Neuroimmune interaction and neuroinflammation research technologies
Immunotherapeutic and vaccine development platforms for neurodegenerative diseases
Organoid, microphysiological, and human tissue modeling systems
Computational neuroscience and neuroimmunology simulation platforms
Microbiome and infectious disease analytics related to neurodegeneration
Precision diagnostics and early detection technologies for Alzheimer’s disease
Immunophenotyping and immune-aging monitoring systems
Environmental exposure and exposome analytics platforms
Autoimmunity and neurodegeneration biomarker research tools
Longitudinal cognitive monitoring and digital health assessment systems
Translational neuroscience and neurodegenerative disease modeling technologies
Predictive analytics for cognitive decline and disease progression
Behavioral, social, and environmental factor integration platforms
Multi-omics and systems biology technologies for aging brain research
Novel therapeutic target discovery and validation systems
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, software engineering, cloud infrastructure, AI model development, computational modeling, bioinformatics analysis, preclinical studies, organoid research, environmental health analytics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable neuroscience or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
